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Chronic lymphocytic leukemia is associated with a highly hetero-geneous disease course in terms of clinical outcomes and respons-es to chemoimmunotherapy. This heterogeneity is partly due to
genetic aberrations identified in chronic lymphocytic leukemia cells such
as mutations of TP53 and/or deletions in chromosome 17p [del(17p)],
resulting in loss of one TP53 allele. These aberrations are associated with
markedly decreased survival and predict impaired response to chemoim-
munotherapy thus being among the strongest predictive markers guiding
treatment decisions in chronic lymphocytic leukemia. Clinical trials
demonstrate the importance of accurately testing for TP53 aberrations
[both del(17p) and TP53mutations] before each line of treatment to allow
for appropriate treatment decisions that can optimize patients’ outcomes.
The current report reviews the diagnostic methods to detect TP53 disrup-
tion better, the role of TP53 aberrations in treatment decisions and cur-
rent therapies available for patients with chronic lymphocytic leukemia
carrying these abnormalities. The standardization in sequencing tech-
nologies for accurate identification of TP53 mutations and the impor-
tance of continued evaluation of TP53 aberrations throughout initial and
subsequent lines of therapy remain unmet clinical needs as new thera-
peutic alternatives become available. 
Introduction
Chronic lymphocytic leukemia (CLL) is associated with a highly heterogeneous
disease course, with some patients surviving for more than 10 years without need-
ing treatment, and others experiencing rapid disease progression and poor out-
comes despite effective chemoimmunotherapy.1-3 This heterogeneity is partly
explained by the diverse genetic aberrations identified in CLL patients.4-6 In partic-
ular, deletions in chromosome 17p [del(17p)] resulting in loss of the TP53 gene,
which encodes the tumor-suppressor protein p53, are associated with a poor prog-
nosis. Furthermore, mutations of TP53 are also associated with poor prognosis
independently of the presence of del(17p).7 Collectively, these deletions and muta-
tions will be referred to as TP53 aberrations. 
TP53 aberrations belong to the strongest prognostic and predictive markers guid-
ing treatment decisions in CLL, and are associated with markedly decreased sur-
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ABSTRACT
vival and impaired response to chemoimmunotherapy.8-12
Until recently, the only effective treatments available for
patients with CLL harboring TP53 aberrations were alem-
tuzumab and allogeneic hematopoietic stem cell trans-
plantation.13-17 New small-molecule inhibitors that are effi-
cacious in patients harboring TP53 aberrations are now
available, including the Bruton tyrosine kinase (BTK)
inhibitor ibrutinib, the phosphatidylinositol 3-kinase
(PI3K) inhibitor idelalisib, and the BCL2 inhibitor veneto-
clax.18-26 Identifying TP53 aberrations is therefore impor-
tant for determining the most appropriate course of treat-
ment for patients with CLL.27
Several diagnostic techniques are currently in routine
use for the identification of TP53 aberrations. A substan-
tial proportion of TP53 aberrations involve TP53 muta-
tions in the absence of del(17p).12,28-31 Therefore, while
del(17p) is routinely identified by fluorescence in situ
hybridization (FISH), FISH testing alone may potentially
fail to identify approximately 30-40% of patients with
TP53 aberrations, i.e those carrying only mutations in
the gene.32,33 Thus, it is critical to test for relevant TP53
mutations, using Sanger sequencing or high-throughput
sequencing technologies, in addition to FISH detection
of del(17p), and both tests should be performed before
each line of therapy to select appropriate treatment, as
TP53 aberrations may emerge during the disease course
and after previous treatment.27,31,34 The European
Research Initiative on CLL (ERIC) has implemented a
certification program (known as the TP53 Network) for
clinical laboratories performing analysis of TP53 aberra-
tions in order to improve the reliability of TP53 muta-
tion analysis and to spread knowledge on testing for
TP53 aberrations in routine clinical practice, with the
final aim of optimizing treatment choices and patients’
outcomes.35
Genetic aberrations in chronic lymphocytic leukemia
Genetic aberrations identified in CLL include genomic
abnormalities and specific gene mutations.6,36
Combinations of these aberrations, along with
immunoglobulin heavy variable (IGHV) mutation status,
result in biological and clinical subgroups associated with
varying outcomes.10,11,37,38 An overview of the genetic aber-
rations frequently found in CLL is provided in Table 1. 
Chromosomal abnormalities frequently found in CLL
include del(13q), trisomy 12, del(11q), and del(17p);4 other
less frequent abnormalities have also been identified such
as amplifications of chromosome 2p or 8q, and deletions
in chromosomes 8p and 15q.4,36 
Using conventional karyotyping of stimulated lympho-
cytes, the presence of three or more chromosomal abnor-
malities, known as a complex karyotype, has been associ-
ated with worse disease outcomes.39-42 Similar results have
been obtained using arrays for DNA copy number alter-
ations to detect genomic complexity.37,43 There is a strong
association of complex karyotype with TP53 aberrations
leading to genetic instability, but a complex karyotype has
been demonstrated to be an independent prognostic factor
for poor overall survival.28,39,40,44,45 Chromothripsis-like pat-
terns, defined by tens to hundreds of chromosomal
TP53 aberrations in CLL
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Table 1. Overview of genetic complexity in chronic lymphocytic leukemia.
Genetic                                                Frequency in       Time to first            PFS                    OS               Coexistence with                                    References
aberration                                              untreated           treatment         (median,           (median,          other genetic aberrations
                                                                 patients       (median, months)    months)            months)           
  del(17p)                             4–8.5%                          9                            -                        31–33a               TP53mutations                                            (4, 8, 11, 28, 56)
  del(11q)                             17–18%                        13                           -                        72–79a               ATM and/or SF3B1, BIRC3mutations        (4, 11, 28, 56)
                                   Trisomy 12                          12–16%                        33                           -                       97–114a              NOTCH1mutations                                       (4, 11, 28, 56)
Chromosomal        del(13q)                             35–55%                        92                           -                      113–133a             miRNA 15a/16-1 encoded within DLEU2  (4, 11, 28, 56)
abnormalities                                                                                                                                                                                intron in 13q23                                                            
                                   Other (e.g. amp[2p];        2–7%                           -                            -                             -                     -                                                                          (4, 11, 28, 56)
                                   amp[8q]; del[8p]; 
  del[15q]; and del[6q])
                                   TP53                                      5–12%                       4–58                    4–23b                   21–90b               The majority of clonal mutations          (5, 6, 8, 10, 28, 31, 
                                                                                                                                                                                                          are associated with del(17p)                    36, 56, 73, 110)
                                                                                                                                                                         Mostly associated with U-CLL                                
                                   NOTCH1                              10–14%                      5–42                   18–86b                  15–34b               Mostly in U-CLL (82%)
                                                                                                                                                                                                          Frequently associated with trisomy 12     (6, 10, 28, 31, 
                                                                                                                                                                                                                                                           36, 56)
Gene mutation      SF3B1                                   9–14%                       2–86                    5–43b                   28–90b               Found together with TP53mutations     (5, 6, 28, 31, 36)
                                                                                                                                                                         in some studies, but not in others                        
                                   ATM                                      11–26%               Significantly             8–40b                   26–85b               ATM and del(11q) occur mostly                 (5, 6, 28, 31, 
                                                                                                   reduced independently                                                           in U-CLL                                                                 36, 56)
                                                                                                             of del(11q)
                                   Other (e.g. FAT1,                                                     -                       RPS15:                  RPS15:               RPS15 can be exclusive of TP53                (36, 52, 54, 73)
  MYD88, POT1, and RPS15)                                                        reduced PFS       reduced OS          mutations                                                                     
U-CLL: IGHV unmutated CLL; aIn previously untreated patients bAcross all lines of treatment in chemoimmunotherapy studies. CLL: chronic lymphocytic leukemia; OS: overall survival;
PFS: progression-free survival; WT: wild type.
rearrangements in a localized region of the genome, have
also been identified in some patients with CLL,46-48 usually
associated with TP53 and SETD2 mutations.6,49
Apart from TP53, the most frequent mutations associat-
ed with disease outcomes in CLL are found in the ATM,
BIRC3, NOTCH1, and SF3B1 genes.6,31,50-53 These and other
mutations have been associated with the development of
high-risk disease, with a higher incidence of these muta-
tions being found in fludarabine-refractory CLL than in
untreated CLL.6,52,54-56 The impacts of these mutations on
outcomes in CLL are outlined in Table 1 but the clinical
value of each of them remains to be established.57
IGHV gene status
Another important CLL feature that affects prognosis is
the IGHV gene mutation status. The clinical course is gen-
erally more aggressive in patients with unmutated IGHV
genes than in those with mutated IGHV genes.58,59 TP53
mutations may be found in both mutated and unmutated
CLL, but are usually associated with unmutated CLL.56
Immunogenetic studies have recently revealed that
approximately one third of patients with CLL carry quasi-
identical or stereotyped B-cell receptors (BCR) and can be
grouped into subsets that share clinico-biological features
and outcome.57
What is TP53? 
Over 50% of human cancers carry TP53 gene muta-
tions,60 and the importance of TP53 in tumor development
is highlighted by the increased incidence of cancer before
the age of 30 in patients with Li-Fraumeni syndrome,
which results from germline mutations in the TP53 gene.61 
TP53 encodes the tumor-suppressor protein p53, which
has numerous cellular activities including regulation of the
cell cycle and apoptosis, and promotion of DNA repair in
response to cellular stress signals such as DNA dam-
age.60,62,63 Following DNA damage, p53 triggers either
apoptosis or G1 cell-cycle arrest until the cell has complet-
ed DNA repair processes, thereby preventing replication
of potentially harmful genetic abnormalities.62
What are the different types of TP53 aberration and
how do they affect p53 function and pathogenicity?  
TP53 aberrations can arise through deletion of the TP53
locus on chromosome 17 (17p13.1) or gene mutations
including missense mutations, insertions or deletions
(indels), nonsense mutations or splice-site mutations.
Gene mutations are heavily concentrated in the DNA-
binding domain, encoded by exons 4–8 of the TP53 gene,
but mutations can also appear in the oligomerization
domain or C-terminal domain.33,63-65 del(17p) and/or TP53
mutations in various combinations can result in the loss of
wildtype p53 function in CLL (Figure 1).12,28,29,31,33 Six
‘hotspot’ codons in particular (codons 175, 245, 248, 249,
273, and 282) are affected at elevated frequency.33,63,66 This
is in line with a disease-specific TP53mutational profile in
CLL.66
The most commonly found mutations in TP53 are mis-
sense mutations in the coding region of TP53, which lead
to an amino acid change in the p53 protein and account
for approximately 75% of TP53 mutations identified.33,60,63
Missense mutations may result in expression of a mutated
p53 protein that cannot activate the p53 tumor-suppres-
sive transcriptional response, have dominant-negative
effects over any remaining wildtype p53, and/or could
gain oncogenic functions independent of wildtype
p53,5,33,60,64 illustrating their pathogenic and prognostic
impact even if occurring in one copy (mono-allelic) of
TP53 with retention of a potentially functional allele.32 In
contrast, del(17p), frameshift mutations, indels, nonsense
mutations, and splice-site mutations result in loss of func-
tional p53, and although functional p53 may still be
expressed in the presence of a second wildtype allele, this
has not been proven to diminish the adverse prognostic
impact of such abnormalities (Figure 2).33
Based on data obtained from Sanger sequencing,
approximately 80% of patients harboring del(17p) also
carry TP53 mutations in the second allele.8,30,67 Overall,
del(17p) associated with TP53mutations is the most com-
mon abnormality affecting the TP53 gene in CLL, account-
ing for approximately two-thirds of cases.8,10,30,33 The
E. Campo et al.
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Figure 1. Loss of wildtype (wt) p53 function in chronic lymphocytic leukemia can occur as a result of del(17p) and/or TP53 mutations.12,28,29,31,33 The most common
cause of TP53 aberrations is the result of a combination of TP53 mutation and del(17p), which accounts for up to two-thirds of all TP53 aberrations. 
remaining cases with TP53 aberration carry either gene
mutation(s) or sole del[17p].28,29,31,33 A TP53mutation can be
accompanied by a copy-number neutral loss of heterozy-
gosity of the second TP53 allele.5,6,30,31
Clonality and clonal evolution 
Individual cancer samples are genetically heterogeneous
and contain clonal and subclonal populations.68,69 These
populations may be in equilibrium, with the relative pro-
portions of each subclone remaining stable, or may under-
go evolution, with some subclones emerging as
dominant.50 While most untreated CLL, and a minority of
treated CLL, maintain stable clonal equilibrium, treatment
may shift the architecture in favor of one or more aggres-
sive subclones.50 This clonal evolution is a key feature of
cancer progression and relapse, with tumors likely evolv-
ing through competition and interactions between geneti-
cally diverse clones (Figure 3).5 In CLL, clonal evolution
after treatment or at the time of relapse has been identi-
fied as ‘the rule, not the exception’.5,70 In a study by Landau
et al.,5 47 out of 49 patients with CLL had clonal evolution
at the time of relapse. Importantly, chemoimmunotherapy
pressure is thought to lead to clonal evolution, most
prominently for TP53 aberrant subclones.71
TP53 aberrations are indeed strongly associated with
clonal evolution in CLL.44,72,73 TP53 aberrations are less fre-
quent at diagnosis (Table 1), while 40–50% of cases with
advanced or therapy-refractory CLL harbor aberrations,
highlighting the need to re-assess TP53 status before each
line of treatment because the clones could expand at
relapse and/or during disease progression.8,10,56,74 Single or
multiple minor subclones harboring TP53 mutations may
be present before therapy or may develop during relapse
at any stage. These TP53-mutant minor subclones are
often present at very low frequencies that may be unde-
tectable by Sanger sequencing and are highly likely to
expand to dominant clones under the selective pressure of
chemoimmunotherapy.12,31,51
How do we test for and report TP53 aberrations? 
Techniques frequently used for assessing TP53 status in
CLL include FISH for del(17p), Sanger sequencing, and
next-generation sequencing for TP53 mutations (Table
2).27,35,74,75 As TP53 mutations are associated with a poor
prognosis independently of the presence of del(17p),7 it is
important to assess for TP53 mutation status using a
sequencing technique.27,35
Sequencing of the TP53 gene
TP53 sequencing should cover exons 4–10 (correspond-
ing to the DNA binding domain at codons 100–300 and
the oligomerization domain at codons 323–365) at a min-
imum. Sequencing of the whole coding region (exons 2–
11) and adjacent splice sites is highly recommended using
either bidirectional Sanger sequencing or next-generation
sequencing, as studies of the latter have shown that vari-
ants can also occur in exons outside the DNA binding
domain although their frequency is low (Figure 2).35
Sanger sequencing is a widely and routinely used tech-
nique to assess TP53 status in CLL in clinical practice. The
technique provides a relatively simple, accessible sequenc-
ing approach, but is time-consuming and lacks sensitivity
for detecting minor subclones harboring TP53 mutations,
with a detection limit for mutated alleles of 10–
TP53 aberrations in CLL
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Figure 2. TP53 gene organization and distribution of mutations by codon.63,121,122 The TP53 gene is located at the p13.1 locus on the short arm of chromosome 17
and comprises 11 exon sequences that encode for the p53 protein. While the majority of gene mutations cluster within the DNA-binding domain (codons 100–300,
exons 4–8), gene mutations have been detected in almost every codon. Sequencing should, therefore, cover the DNA-binding domain and oligomerization domain
as a minimum (exons 4–10), but sequencing of the whole coding region (exons 2–11) is highly recommended.
20%.27,29,35,76-78 As stated earlier, minor TP53-mutant sub-
clones that may be missed by Sanger sequencing also
appear to carry the same unfavorable prognostic impact as
clonal TP53 mutations.7,12,31,51,69
Next-generation sequencing technologies include target-
ed next-generation sequencing, which has good correla-
tion with Sanger sequencing in comparison stud-
ies12,28,31,35,75,78 and detects low-frequency mutations below
the threshold for Sanger sequencing.38,79-81 The sensitivity
threshold varies depending on a number of variables,
including the hardware, methods used for testing and the
analytical pipeline, and should be defined by each labora-
tory using standardized criteria or equivalent medical lab-
oratory standards.35,75
Reports of TP53 mutational analysis should always
include the type of analysis and methodology used, the
exons analyzed, the limit of detection, and coverage for
next-generation sequencing (median and ≥99% mini-
mum).35 Low-level TP53 mutations occurring in <10% of
DNA that may be subject to further clonal selection are
also identified by next-generation sequencing. Recent rec-
ommendations on the methodological approaches for
TP53mutation analysis from The TP53Network of ERIC35
concluded that the clinical importance of mutations in
Figure 3. An example of possible clonal evolution scenarios across the course of disease in chronic lymphocytic
leukemia.28,50 Genomic diversification of CLL occurs through sequential acquisition of gene mutations, represented
by clones of different colors. Treatment may reduce or eliminate the incumbent clone, shifting the clonal architec-
ture in favor of one or more aggressive subclones. Different therapies may preferentially provide selective advan-
tages for different mutations. For example, the red circles are TP53-mutated clones, which have been selected for
by chemotherapy, whereas the turquoise clones would have acquired resistance to the targeted therapy.
Table 2. Comparison of methods for the detection of TP53 aberrations.
Method          Description                                                                    Advantages                                                         Disadvantages                                   References
FISH                  FISH uses fluorescent DNA probes to target                     • Rapid evaluation of fresh cells or                         • Can only detect genetic defects         (111-114)
                            specific chromosomal locations within the nucleus          paraffin-embedded interphase nuclei                  recognized by a specific probe
                            that can be detected by fluorescence microscopy             • Widely used in routine clinical practice               • Cannot detect copy-neutral loss                 
                                                                                                                                     • High specificity                                                           of heterozygosity
Sanger              Sanger sequencing uses selective incorporation of         • Simple and widely available                                     • Relatively time-consuming            (27, 29, 35, 76-78)
sequencing      chain-terminating dideoxynucleotides by DNA                   • Provides direct information on mutation type   • Limited sensitivity (usually 
                            polymerase during DNA replication, thereby                      • Can produce relatively long read lengths            approximately 10–20% of mutant 
                            creating sequences of various lengths, which are             • High specificity (~93%)                                           alleles)
                            then separated by size to derive the DNA sequence                                                                                                    • Limited throughput
NGS                   NGS covers a range of technologies that                             • High and customizable sensitivity                          • Upfront cost of instrumentation,    (6, 27, 29, 31, 
                            allow high-throughput sequencing of millions                    • Simultaneous analysis of large numbers            although some NGS sequencers        35, 76-78)
                            or billions of DNA strands in parallel                                     of genes                                                                        are now cheaper than capillary 
                                                                                                                                     • No PCR with some platforms                                  sequencers (for Sanger)
                                                                                                                                     • Very high specificity (100%)                                    • High throughput needed for 
                                                                                                                                                                                                                                cost-effectiveness                                           
Genomic          A technique that allows high-resolution,                              • Provides high resolution, genome-wide               • High cost                                                  (43, 44, 48, 
arrays               genome-wide screening of segmental copy number        information                                                                  • Cannot detect balanced                         115-117)
                            aberrations                                                                                   • Can detect genomic imbalances                            rearrangements i.e. translocations, 
                                                                                                                                     (deletions/amplifications) and                              balanced insertions, inversions
                                                                                                                                     copy-neutral loss of heterozygosity                       
FISH: fluorescence in situ hybridization; NGS: next-generation sequencing; PCR: polymerase chain reaction.
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<10% of alleles within the cancer cell population remains
an unresolved issue and there is not enough evidence to
make therapeutic decisions based on mutations unde-
tectable by Sanger sequencing. This conclusion should be
always stated when reporting variants present at a fre-
quency of below 10%.
Outside of the context of research, determination of
TP53 status at diagnosis may not be required; initiation of
first-line treatment can be deferred until patients have
symptomatic active disease irrespective of TP53 status.82-85
Naming, reporting, and pathogenicity of mutations
The consistent use of nomenclature in managing DNA
sequence mutations is essential for concise communica-
tion of diagnostic testing and genetic risk assessment.60 In
clinical practice, aberrations are often referred to as
mutations, and are referred to as such in clinical reports.
However, one must note that the more accurate techni-
cal term is ‘variant’. It is recommended that mutations
are named according to the Human Genome Variation
Society guidelines, or according to American College of
Medical Genetics guidelines on mutations and mutation
pathology in the case of germline mutations.86,87
Description of mutations at the DNA level using the sta-
ble Locus Reference Genomic reference sequence is rec-
ommended to enable comparison across studies and
databases.88
The pathogenicity of more frequent TP53 mutations is
well known, with functional analyses demonstrating that
all TP53 hot-spot mutations result in a clear loss of p53
activity.5,60 The pathogenicity of some less frequently
occurring TP53mutations may be less clear, particularly in
the case of missense mutations which can have varied
functional consequences.5,33,60,64
A combination of factors are considered when deter-
mining whether a mutation is likely to be pathogenic,
including whether the mutation results in an amino acid
change, whether the mutation is found in a conserved
region of the genome or hotspot region, and whether
there is a predicted functional effect of the amino acid
splicing change on the protein or post-translational modi-
fication.60 Pathogenicity assessments should be performed
by experienced diagnosticians, follow standardized proce-
dures, and be documented. TP53 locus-specific databases
are available and are important tools for analyzing and
assessing the pathogenicity of TP53 mutations. These are
the IARC TP53 database (http://p53.iarc.fr/), the TP53
website (http://p53.fr/), and the Seshat online software
(http://p53.fr/tp53-database/seshat). The Seshat online
software, for example, provides a quality check of the
mutation nomenclature, generates a description of the
mutation, and assesses the pathogenicity of each mutation
with the use of specific algorithms. Structural and func-
tional information for each mutation is also produced.35,89 
Clinical implications of TP53 aberrations
Patients with del(17p) and/or TP53 mutations usually
respond poorly to the standard first-line chemoim-
munotherapy, and have an aggressive disease course.8-12 In
the CLL8 study comparing first-line treatment with flu-
darabine plus cyclophosphamide or fludarabine plus
cyclophosphamide with rituximab, TP53 aberrations were
found to be the strongest prognostic markers in multivari-
able analyses and were associated with markedly reduced
progression-free survival and overall survival (Figure 4).10
Both in front-line and relapsed/refractory settings, treat-
ment with bendamustine plus rituximab was also shown
to be associated with low response rates and poor survival
outcomes in patients with CLL harboring TP53 aberra-
tions.90 Consequently, chemoimmunotherapy is no longer
considered standard therapy for patients with TP53 aber-
rations. Until recently, the anti-CD52 antibody alem-
tuzumab was considered to be the only effective agent
available for patients with TP53 aberrations, despite an
TP53 aberrations in CLL
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Figure 4. Progression-free and overall survival according to TP53 status in the CLL8 study.10 Re-published with permission from The American Society of Hematology,
from: Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Stilgenbauer S et al. Blood. 2014;123(21):3247-3254;
permission conveyed through Copyright Clearance Center, Inc. FC: fludarabine plus cyclophosphamide; FCR: fludarabine plus cyclophosphamide plus rituximab; mut:
mutated; OS: overall survival; PFS: progression-free survival; WT: wild-type. 
Table 3. Overview of clinical evidence from phase 2/3 trials for novel treatments in patients with TP53 aberrations. 
Study/treatment           Population                     TP53 aberrations      Overall response                     PFS in del(17p)/                  OS in del(17p)/        Safety                             Reference
Sponsors                                                             at baseline                  in del(17p)/TP53                  TP53 mutated                     TP53 mutated          (experimental arm, 
                                                                                                               mutated population                 population                           population                 overall population)                
RESONATE-17:                   Adult patients with           del(17p)                           ORR in del(17p) patients           Median PFS (investigator-       Median OS not             Grade 3–5 AE occurring         (21)
A phase 2, open-label,     previously treated            144/144 (100%)               was 64% by independent             assessed) not reached           reached at                     in >5% of patients:
multicenter study             del(17p) CLL or                                                            review and 83% by                        at a median follow-up               11.5 months                  Neutropenia (18%)
of ibrutinib in patients    SLL (n=144)                      TP53mutations               investigator assessment             of 11.5 months                           (prespecified               Pneumonia (13%)
with R/R CLL/SLL              Median age (range):        107/116 (92%)                 (prespecified primary                 (prespecified primary             primary analysis)         Hypertension (13%)                   
and del(17)p                      64 (57-72)                                                                       analysis, median                           analysis)                                                                               Anemia (10%)
Ibrutinib 420 mg OD         ECOG score:                                                                 11.5 months follow-up)                                                                                                               Thrombocytopenia (8%)
                                              0: 49 (34%)                                                                                                                                                                                                                            Atrial fibrillation (6%)
NCT01744691                      ≥1: 95 (66%)                                                                                                                                                                                                                         (24-month extended analysis)
Pharmacyclics LLC.           Median prior regimens
Janssen Research            (IQR): 2 (1–3)
& Development, LLC        
RESONATE: a phase 3,     Adult patients with           del(17p)                           ORR in del(17p)                            Median PFS in del(17p)           Median OS in               Grade 3–5 AE occurred      (18, 99)
open-label, multicenter  R/R CLL/SLL                       127/391 (32%)                 patients treated                            and/or TP53 patients                 del(17p) or TP53         in 56% of patients
study of ibrutinib versus  (n=391)                                                                          with ibrutinib: 89%                        not reached at                            patients not                  treated with idelalisib
ofatumumab in                 Ibrutinib arm.                                                                                                                           19 months follow-up                 reached                          + rituximab and 48% treated
patients with                      Median age (range):                                                   ORR in del(17p)                           in patients treated                    at 19 months                with placebo + rituximab
previously treated            67 (30–86)                                                                      patients treated with                   with ibrutinib                              follow-up in                  Grade 3–5 AE occurred
CLL/SLL                               ECOG score:                                                                 ofatumumab: 20%                                                                                patients treated          in >5% of patients:
Ibrutinib 420 mg                0: 79 (41%)                                                                  (median follow-up                       Median PFS in del(17p)           with ibrutinib                Idelalisib + rituximab
OD versus ofatumumab   1: 116 (59%)                                                                19 months)                                     and/or TP53 patients                                                          Neutropenia (34%)
                                              Median prior                                                                                                                            5.8 months in patients              Median OS not             Thrombocytopenia (10%)
NCT01578707                      regimens: 3 (1–12)                                                                                                                 treated with ofatumumab       reported in                    Placebo + rituximab
                                              Ofatumumab arm.                                                                                                                                                                          del(17p) or TP53         Neutropenia (22%)
Pharmacyclics LLC.           Median age (range):                                                                                                              Patients with both del17p        patients treated           Thrombocytopenia (16%)
Janssen Research &         67 (37–88)                                                                                                                                and TP53mutation                    with ofatumumab        Anemia (14%) (overall 
Development, LLC            ECOG score:                                                                                                                            (n=38) had worse                                                              study population)
                                              0: 80 (41%)                                                                                                                            PFS compared with 
                                              1:116 (59%)                                                                                                                           patients with neither of
                                              Median prior regimens:                                                                                                        these abnormalities
                                              2 (1–13)                                                                                                                                    (n=68) (P=0.0381) 
                                                                                                                                                                                                   at a median follow-up of 
                                                                                                                                                                                                  19 months                                    
                                              
Study 101-08: a phase 2    Older patients                   del(17p) only:                 ORR in either del(17p)               Median PFS in del(17p)           Median OS in                Grade 3–5 AE occurred          (22)
study of idelalisib plus     (≥65 years) with              2/64 (3.1%)                       or TP53mutation: 100%               and/or TP53 patients not         del(17p) and/or           in 89.1% of patients.
rituximab in elderly          previously untreated                                                                                                              reached after a median           TP53 patients not        Grade 3–5 AE occurred
patients with untreated  CLL or SLL (n=64)           TP53mutation only:                                                                  22.4 months on treatment       reached after a            in >5% of patients:
CLL or SLL                          Median age (range):        3/63 (4.7%)                                                                                                                                        median of                      Diarrhea and/or 
Idelalisib 150 mg BD        71 (65–90)                          Either del(17p) or                                                                                                                           22.4 months on            colitis (42%)
plus rituximab                    ECOG score/Karnofsky   TP53mutation:                                                                                                                                 treatment                      Pneumonia (19%)
                                              status: not reported         9/64 (14.1%)                                                                                                                                                                               (overall study population)
NCT01203930                      Median prior                     
                                              regimens: 0                         Both del(17p) and
Gilead Sciences                                                             TP53mutation: 
                                                                                            4/64 (6.3%)                       
                                                                                                                                                                                                   
Study 116: a randomized,  Adult patients with R/R    del(17p) and/or             ORR in del(17p)                            Median PFS in del(17p)           Not reported in            Grade 3–5 AE occurred      (19, 23)
double-blind, placebo-     CLL not eligible                TP53mutations               and/or TP53 patients                    and/or TP53 patients                 del(17p) and/or           in 56% of patients
controlled study of           for cytotoxic                                                                   treated with                                    treated with idelalisib              TP53 patients                treated with idelalisib
idelalisib in                         agents (n=220);                Idelalisib + rituximab    Idelalisib plus                                plus rituximab:                                                                    + R and 48% treated
combination with              PD within 24 months        46/110 (42%)                   rituximab: 77%                               not reached                                                                         with placebo + rituximab
rituximab for previously    of last treatment                                                                                                                                                                                                                     Grade 3–5 AE occurred
treated CLL                         Idelalisib + rituximab      Rituximab:                       ORR in del(17p)                           Median PFS in del(17p)                                                    in >5% of patients:
Idelalisib 150 mg                Median age (range):        50/110 (45%)                   and/or TP53 patients                    and/or TP53 patients                                                         Idelalisib + rituximab arm:
BD plus rituximab versus  71 (48–90)                                                                      treated with                                    treated with rituximab:                                                     Neutropenia (34%)
placebo plus rituximab    ECOG score/Karnofsky                                               rituximab: 15%                               4.0 months (second                                                           Thrombocytopenia (10%)
                                              status: not reported                                                    (second interim                            interim analysis)                                                                Placebo + rituximab arm:
NCT01539512                      Median prior regimens:                                              analysis, median                                                                                                                            Neutropenia (22%)
                                              3 (1–12)                                                                          exposure 5 months                                                                                                                       Thrombocytopenia (16%)
Gilead Sciences                 Placebo + rituximab arm.                                            with idelalisib,                                                                                                                               Anemia (14%)
                                              Median age (range):                                                    4 months with                                                                                                                                (overall study population)
                                               71 (47–92)                                                                      rituximab)
                                               ECOG score/Karnofsky
                                               status: not reported
                                               Median prior regimens: 
                                              3 (1–9)                                continued on the next page
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Study 115:                             Adult patients with           del(17p) and/or              ORR in del(17p)                            Median PFS in del(17p)          Median OS in               Grade 3–5 AE                          (118)
a randomized,                     R/R CLL (n=416);             TP53mutations               patients treated                            and/or TP53 patients                 del(17p) and/or           occurring in ≥5%
double-blind and               PD within 36 months                                                    with idelalisib                                 treated with idelalisib              TP53 patients                of patients:
placebo-controlled           of last treatment               Idelalisib + BR:              + BR: 22/38 (58%)                         + BR: 11.3 months                    treated with                  Idelalisib + BR:
study of idelalisib in          Idelalisib + BR                  69/207 (33%)                                                                                                                                     idelalisib + BR:            Neutropenia (60%) 
combination with             Median age (range):                                                   ORR in del(17p)                            Median PFS in del(17p)          not reached at a           Febrile neutropenia (23%)
bendamustine and            62 (56–69)                          BR: 68/209 (33%)            patients treated with                   and/or TP53 patients                 median follow-up        Placebo + BR:
rituximab (BR) for            ECOG score/                                                                  BR: (9/40) 23%                               treated with BR: 8.3 months   of 14 months                 Neutropenia (47%)
previously treated CLL     Karnofsky status:                                                                                                                                                                                                                     Thrombocytopenia (13%)
Idelalisib 150 mg BD         not reported                                                                                                                                                                                    Median OS in               (overall study population) 
plus BR versus BR              Median prior                                                                                                                                                                                   del(17p) and/or
                                               regimens: 2 (1–4)                                                                                                                                                                          TP53 patients
NCT01569295                       Placebo plus BR                                                                                                                                                                             treated with BR:
                                               Median age (range):                                                                                                                                                                     20.3 months
Gilead Sciences                  64 (56–70)
                                               ECOG score/
                                               Karnofsky status: 
                                               not reported
                                               Median prior 
                                              regimens: 2 (1–4)             
Study 119: a phase 3,         Adult patients with           del(17p) and/or             ORR in del(17p)                            Median PFS in del(17p)           Median OS in               Grade 3–5 TEAE                   (20, 96)
randomized, controlled    R/R CLL (n=261); PD       TP53mutations               and/or TP53 patients                    and/or TP53 patients                 del(17p) and/or           occurring in ≥5% of 
study evaluating the          within 24 months of                                                     treated with                                    treated with idelalisib              TP53 patients                patients treated with 
efficacy and safety            last treatment                    Idelalisib plus                 idelalisib plus                                 plus ofatumumab:                     treated with                  idelalisib plus 
of idelalisib (GS-1101)     Idelalisib plus                    ofatumumab:                   ofatumumab:                                  15.5 months                                 idelalisib +                    ofatumumab:
in combination with          ofatumumab                       70/174 (40%)                   not reported                                                                                          ofatumumab:                Neutropenia (34%)
ofatumumab for                 Median age (range):                                                                                                              Median PFS in del(17p)           25.8 months                   Diarrhea (20%)
previously treated CLL     68 (61–74)                          Ofatumumab:                  ORR in del(17p)                           and/or TP53 patients                                                          Pneumonia (16%) 
                                               Karnofsky status:              33/87 (38%)                     and/or TP53 patients                    treated with ofatumumab:       Median OS in                Anemia (14%) 
Idelalisib 150 mg BD +     80 (80–90)                                                                      treated with                                   5.8 months                                  del(17p) and/or           Febrile neutropenia (12%) 
ofatumumab versus           Median prior                                                                 ofatumumab:                                                                                         TP53 patients                Thrombocytopenia (11%)
ofatumumab alone            regimens: 3 (2–4)                                                        not reported                                                                                          treated with                  Hypokalemia (8%) 
                                               Ofatumumab alone                                                                                                                                                                        ofatumumab:                Pyrexia (7%)                                 
NCT01659021                       Median age (range):                                                                                                                                                                     19.3 months                   Dyspnea (6%)
                                               67 (62–74)                                                                                                                                                                                                                                Hypertension (5%)
Gilead Sciences                  Karnofsky status:                                                                                                                                                                                                                    Dehydration (5%) 
                                               80 (80–90)                                                                                                                                                                                                                                Fatigue (5%) 
                                               Median prior                                                                                                                                                                                                                            Grade 3–5 TEAE
                                               regimens: 3 (2–5)                                                                                                                                                                                                                   occurring in ≥5% 
                                                                                                                                                                                                                                                                                                    of patients treated with
                                                                                                                                                                                                                                                                                                    ofatumumab:
                                                                                                                                                                                                                                                                                                    Neutropenia (16%) 
                                                                                                                                                                                                                                                                                                    Pneumonia (8%) 
                                                                                                                                                                                                                                                                                                    Thrombocytopenia (7%) 
                                                                                                                                                                                                                                                                                                    Anemia (6%) 
                                                                                                                                                                                                                                                                                                    Fatigue (5%) (overall
                                                                                                                                                                                                                                                                                                  study population)                        
A phase 2 open-label        Adult patients with           del(17p)                           ORR in del(17p)                           Median PFS in del(17p)           Median OS in                Grade 3–5 AE in                  (24, 119)
study of the efficacy         R/R CLL with del(17p)     100%                                  patients: 79.4%                              patients: not reached at           del(17p) patients:       del(17p) patients 
of ABT-199 (GDC-0199)    (n=107)                                                                          (independent review                   a median follow-up of              not reached at             occurring in 76% of
in subjects with R/R          Median age (range):        TP53mutated                 committee                                      12.1 months                                 median follow-up        patients
or previously untreated   67 (37–85)                          60/107 (72%)                   assessment)                                                                                        of 12.1 months              Grade 3–5 AE
CLL harboring the             ECOG score n (%):                                                                                                                                                                                                                occurring in ≥5% of
17p deletion                        0: 42 (39%)                                                                                                                                                                                                                            patients: 
                                               1: 56 (52%)                                                                                                                                                                                                                            Neutropenia (40%)
Venetoclax 400 mg OD      2: 9 (8%)                                                                                                                                                                                                                                Anemia (18%) 
                                               Median prior                                                                                                                                                                                                                            Thrombocytopenia (15%)
NCT01889186                       regimens (IQR):                                                                                                                                                                                                                     Autoimmune hemolytic 
                                               2 (1–4)                                                                                                                                                                                                                                      anemia (7%) 
AbbVie                                                                                                                                                                                                                                                                                       Febrile neutropenia (5%)
Genentech, Inc.                                                                                                                                                                                                                                                                       Pneumonia (5%) 
                                                                                                                                                                                                                                                                                                    Immune thrombocytopenic 
                                                                                                                                                                                                                                                                                                    purpura(5%) 
                                                                                                                                                                                                                                                                                                    Tumor lysis syndrome (5%)
                                                                                                                                                                                                                                                                                                  Leukopenia (5%)
Study/treatment            Population                     TP53 aberrations      Overall response                     PFS in del(17p)/                  OS in del(17p)/        Safety                             Reference
Sponsors                                                              at baseline                  in del(17p)/TP53                 TP53 mutated                     TP53 mutated          (experimental arm, 
                                                                                                               mutated population                 population                            population                overall population)                
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overall limited efficacy and a high risk of opportunistic
infectious complications.16 Allogeneic hematopoietic stem
cell transplantation is a potentially curative therapeutic
option for patients with TP53 aberrations, but is only fea-
sible for highly selected younger, physically fit patients
and those who have obtained a good therapeutic
response.13,15,17
Therapies with p53-independent mechanisms of action
Recent developments in the treatment options for
patients with CLL harboring TP53 aberrations include
small-molecule kinase inhibitors that target the BCR path-
way (ibrutinib and idelalisib)18-22,26 and the anti-apoptotic
protein BCL2 (venetoclax).24,91-93 Ibrutinib is an inhibitor of
Bruton tyrosine kinase,94,95 whereas idelalisib is an
inhibitor of the PI3K p110δ isoform,19,96 both of which are
involved in mediating intracellular signaling from several
receptors including the BCR. Venetoclax is a BH3-mimetic
inhibitor of BCL2, an anti-apoptotic protein with constitu-
tively elevated expression in CLL.92,97 An overview of the
clinical evidence from phase 2/3 trials for these treatments
in patients with CLL harboring TP53 aberrations is shown
in Table 3. The studies were carried out in varying patient
populations, but overall, these novel therapies produced
responses and favorable survival times in a high propor-
tion of patients harboring TP53 aberrations and represent
a significant advance for this high-risk population com-
pared to chemoimmunotherapy regimes.18-26 It is impor-
tant to note that such therapies achieved similar responses
in patients with relapsed or refractory CLL, irrespective of
risk factors that are associated with poorer responses to
chemoimmunotherapy.92,98-100
Given the improvements seen with these therapies,
accelerated approval programs have made the therapies
available for CLL treatment in the clinic. Currently in
Europe, ibrutinib is licensed as monotherapy for first-line
treatment and for relapsed/refractory patients with CLL, or
in combination with bendamustine plus rituximab in the
relapsed/refractory setting.94 Idelalisib is indicated in combi-
nation with an anti-CD20 monoclonal antibody (rituximab
or ofatumumab) for relapsed/refractory CLL therapy, and as
first-line therapy in patients with del(17p)/TP53 mutations
not suitable for other therapies.96 Venetoclax is currently
licensed in Europe for patients with relapsed/refractory CLL
in whom both chemoimmunotherapy and a BCR inhibitor
have failed, or for patients with del(17p) or a TP53mutation
who are not suitable for BCR inhibitors or in whom BCR
inhibitor treatment has failed.97 Although limited data are
available for all these agents in the treatment-naïve setting,
the approvals as first-line therapy reflect the high level of
unmet need for patients with TP53 aberrations. Moreover,
the development of these novel therapies has produced a
change in therapeutic goals. In particular, frail patients with
progressive CLL can now be treated with the aim of effec-
tively controlling the disease, whereas previously palliative
care would have been the only option.19
MURANO: a randomized,   Adult patients with             del(17p) only                     Not reported                                      del(17p)                                           Not reported                   Grade 3–4 AE in patients        (120)
open-label, phase 3 trial  R/R CLL (n=389):             Venetoclax plus                                                                        Median PFS not reached                                                  receiving venetoclax plus
evaluating venetoclax       Venetoclax plus                 rituximab: 24 (14%)                                                                 with venetoclax plus                                                          rituximab: 82.0% 
plus rituximab versus       rituximab (n=194)           BR 18 (11.4%)                                                                            rituximab at 2-year                                                            Grade 3–4 AE in patients
bendamustine plus           Median age (range):                                                                                                              follow-up                                                                              receiving BR 70.2%
rituximab in R/R CLL         64.5 (28–83) years                                                                                                                  Median PFS 15.4 months                                                  
                                               ECOG score n (%)           TP53mutation only                                                                   with BR
NCT02005471                       0: 111 (57.2%)                 Venetoclax plus                                                                         
                                               1: 82 (42.3%)                  rituximab: 19 (11.1%)                                                              
AbbVie                                   2: 1 (0.5%)                       BR 23 (14.6%)                                                                            TP53mutation 
Genentech, Inc.                  Number of prior                                                                                                                      Median PFS not reached 
                                               therapies n (%):                                                                                                                      with venetoclax plus 
                                               1: 111 (57.2%)                del(17p) and                                                                             rituximab at 2-year
                                               2: 57 (29.4%)                   TP53mutated                                                                             follow-up
                                               3: 22 (11.3%)                   Venetoclax plus                                                                        Median PFS 12.9 months 
                                               >3: 4 (2.1%)                    rituximab: 22 (12.9%)                                                              with BR
                                               BR (n=195)                                                                                                                              
                                               Median age (range):        BR 22 (13.9%)
                                               66 (22–85) years               
                                               ECOG score n (%)
                                               0: 108 (55.7%)
                                               1: 84 (43.3%) 
                                               2: 2 (1.0%)
                                               
                                               Number of prior 
                                               therapies n (%):
                                               1: 117 (60.0%) 
                                               2: 43 (22.1%)
                                               3: 34 (17.4%)
                                              >3: 1 (0.5%)                    
AE: adverse events; ALT: alanine aminotransferase; AST: aspartate aminotransferase; BD: twice daily; BR: bendamustine plus rituximab; CLL: chronic lymphocytic leukemia; ECOG: Eastern
Cooperative Oncology Group; HR: hazard ratio; IQR: interquartile range; OD: once daily; ORR: overall response rate; OS: overall survival; PD: progressive disease; PFS: progression-free survival; R/R:
relapsed/refractory; SLL, small lymphocytic leukemia; TEAE: treatment emergent adverse events.
Study/treatment           Population                     TP53 aberrations      Overall response                     PFS in del(17p)/                  OS in del(17p)/        Safety                             Reference
Sponsors                                                            at baseline                  in del(17p)/TP53                 TP53 mutated                     TP53 mutated          (experimental arm, 
                                                                                                               mutated population                 population                           population                overall population)                
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It has also become evident that patients may develop
resistance to these targeted therapies. For example, muta-
tions in the BTK and PLCG2 genes have been associated
with resistance to ibrutinib, while upregulation of anti-
apoptotic BCL2 family members has been associated
with resistance to venetoclax.101-104 Mechanisms of resist-
ance to idelalisib have not yet been fully characterized;
because idelalisib inhibits the PI3K p110δ isoform, resist-
ance may theoretically involve upregulation of other PI3K
isoforms.105 However, in a whole-exome sequencing
analysis of 13 patients with CLL who had progressed
while on idelalisib plus anti-CD20 treatment in three
phase 3 trials, none of the patients had recurrent progres-
sion-associated mutations in the PI3K pathway or other
related pathways.71
The optimal sequencing of these targeted therapies is
currently unknown, but observational studies suggest
that patients who discontinue a BCR pathway inhibitor
due to toxicity may benefit from an alternative BCR path-
way inhibitor. Conversely, those patients who progress
under BCR inhibitor therapy fare better with venetoclax
than an alternative BCR inhibitor.106,107 Following progres-
sion on one or more therapies, allogeneic hematopoietic
stem cell transplantation also remains a valid option,
especially because these novel therapies may render
patients more fit for this procedure.
It is important to note that, until recently, treatment
guidelines for patients with TP53 aberrations were based
on retrospective analyses and subgroup analyses. Patients
with TP53 aberrations are still defined as a high-risk
group, despite the development of these newer therapies,
but their outcome has greatly improved in recent years.
More long-term data and dedicated trials of these new
therapies in this population are still needed to understand
the long-term prognosis. Nevertheless, these therapies (as
monotherapy or in combination) have become the main-
stay of treatment in patients with CLL harboring TP53
mutations or del(17p), as well as in relapsed or refractory
CLL and have led to recent updates in treatment guide-
lines.34,35,84,85,108,109 
Future considerations
As evidence from clinical trials demonstrates, it is
important to test accurately for TP53 aberrations (both
del[17p] and TP53 mutations) before each line of treat-
ment, thus allowing for appropriate treatment decisions
to optimize patients’ outcomes. Accurate identification of
TP53 mutations demands standardization in sequencing
technologies and pathogenicity assessments.
Independent evaluation within prospective clinical trials
is still required to determine the clinical impact of minor
subclonal mutations (<10%). Similarly, given the contin-
uing evolution of therapeutic agents in CLL, it is impor-
tant to continue to evaluate TP53 aberrations as new ther-
apeutic alternatives become available. While allogeneic
hematopoietic stem cell transplantation remains the only
curative treatment option for patients with CLL harbor-
ing TP53 aberrations, the recent approvals of ibrutinib,
idelalisib, and venetoclax have provided significantly
improved outcomes for this high-risk group of patients. 
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